Head to head
Dr. Reddy's Laboratories vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: RDY · TAK
RDY
Dr. Reddy's Laboratories
14.89+0.40%
1-year price shape — +8% over the period
Quant Rating C · 48/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
| RDY | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 14.89 | 21.77 |
| Change today | +0.40% | +1.68% |
| 1-year return | +7.9% | +57.5% |
| Market cap | $12.41B | $69.76B |
| 52-week range | 11.28 – 15.56 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | 41.36 | 311.00 |
| P/E percentile, own 5-yr range | 99th | 100th |
| P/B | 3.00 | 1.50 |
| Dividend yield | 0.56% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | 0.55 | -0.30 |
| Net profit (TTM) | $459.35M | $-970.94M |
| Revenue (TTM) | $329.84B | $4.69T |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | -1.5% | +6.7% |
| Gross margin | 49.5% | 65.8% |
| Operating margin | 9.5% | 14.3% |
| Net margin | 8.5% | 0.9% |
| Free cash flow (TTM) | $4.74B | $433.95B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 63.7% | 51.3% |
| Insider activity (12mo) | 0 buy / 1 sell | 19 buy / 31 sell |
| Short interest (% of float) | 3.0% | 0.1% |
| Analyst consensus | 67% buy / 33% hold (3) | 100% buy (1) |
| Analyst price target | $14 (-3%) | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | C (48) | C (90) |
| Company | ||
| Employees | 27,527 | 47,029 |
| Founded | 1984 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.